Clinical Trials Directory

Trials / Completed

CompletedNCT00237159

Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
284 (actual)
Sponsor
Novartis Pharmaceuticals · Industry
Sex
Male
Age
18 Years
Healthy volunteers
Not accepted

Summary

It is the aim of this clinical study to evaluate the skeletal-related event rate and tolerability of zoledronic acid in patients with prostate cancer patients and bone metastases.

Conditions

Interventions

TypeNameDescription
DRUGZoledronic acid

Timeline

Start date
2002-10-01
Primary completion
2005-12-01
First posted
2005-10-12
Last updated
2011-03-23

Source: ClinicalTrials.gov record NCT00237159. Inclusion in this directory is not an endorsement.

Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis (NCT00237159) · Clinical Trials Directory